Monthly disclosure on share capital and voting rights May 31, 2026
| Regulated Information |
Issy-les-Moulineaux, June 8, 2026
Sodexo: Monthly disclosure on share capital and voting rights
Pursuant to Article L.233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers
Registered name of the issuer: SODEXO
255, quai de la Bataille de Stalingrad – 92130 ISSY-LES-MOULINEAUX
| Date | Total number of shares | Actual voting rights * | Theoretical voting rights ** |
May 31, 2026 | 147,454,887 | 218,135,145 | 216,509,209 |
* Actual voting rights: all of the Company shares have the same voting rights, except for treasury shares which do not have voting rights and registered shares held for more than four years, which have double voting rights.
** Theoretical voting rights: the number of theoretical voting rights is calculated based on the shares having either single or double voting rights, including treasury shares which would normally be temporarily deprived of voting rights.
About Sodexo
Founded in Marseille in 1966 by Pierre Bellon, Sodexo is the leader in Food and Services, shaping better everyday experiences at every moment in life: work, heal, learn and play. The Group stands out for its independence, its founding family shareholding and its responsible business model. With its services, Sodexo meets all the challenges of everyday life with a dual goal: to improve the quality of life of our employees and those we serve, and contribute to the economic, social and environmental progress in the communities where we operate. Our purpose is to create a better everyday for everyone to build a better life for all. Sodexo is included in the CAC Next 20, CAC SBT 1.5, FTSE 4 Good and DJSI indices.
Key Figures
|
|
Contacts
| Investor Relations | Corporate Legal |
| Juliette KLEIN +33 1 57 75 80 27 [email protected] | Olivia GUILLAUME +33 6 15 20 99 48 [email protected] |
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- Best Crypto to Buy Now Is Not ETH or SOL and Pepeto Proves Why Before
- Solana Price Prediction: Could SOL Reclaim Its $295 High as AlphaPepe Presale Nears Its Biggest Launch Catalysts?
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share